Tengion blueprints $40M IPO

Tengion is joining the ranks of biotech companies planning to start the New Year with an IPO. The developer outlined plans to raise $40.25 million from the sale of common stock. The money would be used to back the development of new regenerative medicine products.

Tengion builds new body parts for patients using their own cells to seed replacement organs. And, like a lot of biotechs, the developer has managed to rack up a string of losses over the years. Tengion plans to go public on Nasdaq at a time a growing number of life sciences companies are dusting off IPO plans following a long dry spell for new offerings.

- here's the story from Dow Jones

Suggested Articles

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.